Literature DB >> 2654650

Smokeless tobacco: association with increased cancer risk.

M E Mattson1, D M Winn.   

Abstract

Smokeless tobacco (chewing tobacco and snuff) contains known carcinogens shown to increase the risk for oral cancer. The effect of snuff has been more fully documented than other forms of smokeless tobacco, although the carcinogenic potential of all such products is acknowledged. Risk increases with increasing length of exposure, with risks greatest for anatomic sites where the product has been held in contact the longest time. In some studies, other organs, such as the esophagus, larynx, and stomach, have been shown to be at increased risk for cancer from the use of smokeless tobacco, although at present the data are insufficient to substantiate fully a causal association. Numerous reports have shown an association between snuff use and leukoplakia, with less evidence at present linking chewing tobacco use with leukoplakia. The documented early onset of the smokeless tobacco habit and reports of increases in certain oral cancers among young men raise serious concerns of an impending oral cancer epidemic in this population. In addition, synergistic interactions with other oral cancer risk factors, e.g., smoking and alcohol, and a high rate for second primaries observed for these cancers add to the concern. Unless the tide of its use is stemmed, long-term use can be expected to produce an increase in oral cancers, and perhaps cancers of other sites, as youthful users mature and accumulate exposure to this carcinogenic agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2654650

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  12 in total

1.  Chewing tobacco: who uses and who quits? Findings from NHANES III, 1988-1994. National Health and Nutrition Examination Survey III.

Authors:  Beth Howard-Pitney; Marilyn A Winkleby
Journal:  Am J Public Health       Date:  2002-02       Impact factor: 9.308

2.  Smokeless tobacco abstinence effects and nicotine gum dose.

Authors:  D Hatsukami; D Anton; R Keenan; A Callies
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Prevalence of alternative forms of tobacco use in a population of young adult military recruits.

Authors:  Mark W Vander Weg; Alan L Peterson; Jon O Ebbert; Margaret Debon; Robert C Klesges; C Keith Haddock
Journal:  Addict Behav       Date:  2007-07-13       Impact factor: 3.913

4.  Correlates of tobacco use among Native American women in western North Carolina.

Authors:  J G Spangler; M B Dignan; R Michielutte
Journal:  Am J Public Health       Date:  1997-01       Impact factor: 9.308

Review 5.  The rodeo athlete: sport science: part I.

Authors:  Michael C Meyers; C Matthew Laurent
Journal:  Sports Med       Date:  2010-05-01       Impact factor: 11.136

6.  Bupropion SR for the treatment of smokeless tobacco use.

Authors:  Lowell C Dale; Jon O Ebbert; Elbert D Glover; Ivana T Croghan; Darrell R Schroeder; Herbert H Severson; Richard D Hurt
Journal:  Drug Alcohol Depend       Date:  2007-03-13       Impact factor: 4.492

7.  Smokeless tobacco use among United States Air Force trainees.

Authors:  Brittany D Linde; Jon O Ebbert; Darrell R Schroeder; Andrew C Hanson; G Wayne Talcott; Robert C Klesges
Journal:  Subst Abus       Date:  2016-12-27       Impact factor: 3.716

8.  Randomized Controlled Trial of the Combined Effects of Web and Quitline Interventions for Smokeless Tobacco Cessation.

Authors:  Brian G Danaher; Herbert H Severson; Shu-Hong Zhu; Judy A Andrews; Sharon E Cummins; Edward Lichtenstein; Gary J Tedeschi; Coleen Hudkins; Chris Widdop; Ryann Crowley; John R Seeley
Journal:  Internet Interv       Date:  2015-05-01

9.  Treating tobacco dependence in a medical setting.

Authors:  Richard D Hurt; Jon O Ebbert; J Taylor Hays; David D McFadden
Journal:  CA Cancer J Clin       Date:  2009-08-25       Impact factor: 508.702

Review 10.  Interventions for smokeless tobacco use cessation.

Authors:  Jon O Ebbert; Muhamad Y Elrashidi; Lindsay F Stead
Journal:  Cochrane Database Syst Rev       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.